The Significance of VSIG4 Expression in Ovarian Cancer
The Significance of VSIG4 Expression in Ovarian Cancer
复制标题
DOI：
10.1097/igc.0000000000000979
复制
发表时间：
2017-06-01
影响因子：
4.8
通讯作者：
Kim, Ki Tae
中科院分区：
文献类型：
--
作者：
Byun, Jung Mi;Jeong, Dae Hoon;Kim, Ki Tae
目的：V-set和含有IG结构域的蛋白4（VSIG 4）是一种新的B7家族相关的巨噬细胞蛋白，具有抑制T细胞活化的能力，在癌症中具有潜在的作用。方法：2011年1月至2015年6月，收集10例卵巢良性肿瘤患者和22例卵巢癌患者手术期间的肿瘤组织和外周血标本。采用逆转录聚合酶链反应（RT-PCR）和蛋白质印迹法（Western blot）分别检测VSIG 4在良性肿瘤和恶性肿瘤组织中的mRNA和蛋白表达水平。通过酶联免疫吸附测定测量可溶性VSIG 4浓度。结果：卵巢癌组织中VSIG 4 mRNA和蛋白的表达水平均高于卵巢良性肿瘤（P分别为0.0013和0.0001）;与良性卵巢肿瘤患者相比，卵巢癌患者中可溶性VSIG 4浓度升高（P = 0.0452）。此外，可溶性VSIG 4水平在晚期和复发性卵巢癌中显著增加（分别为P = 0.0244和0.0288）。VSIG 4在卵巢癌组织中的高表达和血浆中的低表达（可溶性VSIG 4）与较长的无病期相关（P值分别为0.0246和0.0398）。这一发现支持VSIG 4被用作卵巢癌的潜在治疗靶点。此外，可溶性VSIG 4水平与卵巢癌的进展和复发相关，表明可溶性VSIG 4可用作预测肿瘤预后的潜在生物标志物。
Objectives: The protein V-set and Ig domain-containing 4 (VSIG4), a novel B7 family related macrophage protein with the capacity to inhibit T-cell activation, has a potential role in cancer. Here we suggest its possibility as a therapeutic target and prognostic biomarker of ovarian cancer.Methods: Between January 2011 and June 2015, tumor tissues and peripheral blood samples were obtained during surgery from 10 patients with benign ovarian tumors and 22 patients with ovarian cancers. Messenger RNA and protein expression levels of VSIG4 in benign tumor and cancer tissues were examined by the reverse transcription polymerase chain reaction and Western blot, respectively. Soluble VSIG4 concentrations were measured by an enzyme-linked immunosorbent assay. The correlation between VSIG4 expression and the prognosis of ovarian cancer was analyzed according to the patients' clinicopathologic characteristics.Results: VSIG4 messenger RNA and protein expression levels in ovarian cancer tissues were higher than those in benign ovarian tumors (P = 0.0013 and 0.0001, respectively). Soluble VSIG4 concentrations were increased in patients with ovarian cancer compared with that in patients with benign ovarian tumors (P = 0.0452). Moreover, soluble VSIG4 levels were significantly increased in advanced-stage and recurrent ovarian cancer (P = 0.0244 and 0.0288, respectively). High VSIG4 expression of cancer tissue and low VSIG4 expression of plasma (soluble VSIG4) were associated with a longer disease-free interval (P = 0.0246 and 0.0398, respectively).Conclusions: VSIG4 is overexpressed in ovarian cancers compared with that in benign tumors. This finding supports VSIG4 being used as a potential therapeutic target for ovarian cancer. Furthermore, soluble VSIG4 levels are associated with the progression and recurrence of ovarian cancer, indicating that soluble VSIG4 may be used as a potential biomarker for predicting tumor prognosis.